Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.

ABSTRACT:

Introduction

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a major public health concern that is exacerbated by the obesity pandemic. Dietary interventions have the potential to alleviate obesity-associated MASLD through variable mechanisms, including optimizing the gut microbiota. Previously, we reported that soy protein concentrate (SPC) with low or high levels of isoflavone (LIF or HIF) protected young obese Zucker rats from developing liver steatosis. The current study was designed to test whether SPC-LIF and SPC-HIF diets would reverse liver steatosis and alter fecal microbial composition in adult obese Zucker rats with existing steatosis.

Methods

Six-week-old male obese Zucker rats (n = 26) were fed a casein control diet (CAS) for 8 weeks a

SUBMITTER: Hakkak R 

PROVIDER: S-EPMC11551038 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature